BCAX

Bicara Therapeutics Inc. Common Stock

BCAX

Market cap $621M

Overview Fund Activity

11.38 USD

-0.24

2.07%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

11.38

0.00

0%

1 day

-2.07%

5 days

-7.33%

1 month

-2.23%

3 months

13.8%

6 months

-15.7%

Year to date

-32.78%

1 year

-55.21%

5 years

-51.39%

10 years

-51.39%

About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

169% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 16

74% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 19

33% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 8 (+2) [Q2]

14% more funds holding

Funds holding: 92 [Q1] → 105 (+13) [Q2]

4.57% more ownership

Funds ownership: 89.25% [Q1] → 93.82% (+4.57%) [Q2]

25% less capital invested

Capital invested by funds: $633M [Q1] → $475M (-$158M) [Q2]

54% less call options, than puts

Call options by funds: $11K | Put options by funds: $24K

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$36

216% upside

Avg. target

$38

234% upside

High target

$40

251% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Robert Burns	$40	Buy Maintained	22 Aug 2025
Piper Sandler Kelsey Goodwin	$36	Overweight Initiated	19 Aug 2025

See Analyst Rankings

Financial journalist opinion

Bicara Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that management will participate in multiple upcoming investor conferences:

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Zacks Investment Research

Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect?

The consensus price target hints at an 187.7% upside potential for Bicara Therapeutics Inc. (BCAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect?

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX's durability argument and deep response rates could drive long-term value if validated in future studies.

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that members of management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 3:20 p.m. ET.

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m.

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity

The recent stock drop in Bicara Therapeutics Inc. is an overreaction, as the full phase 1/1b data—including key OS results—has yet to be released. BCAX interim data for FICERA plus KEYTRUDA in HPV-negative HNSCC patients showed a 64% ORR, exceeding historical benchmarks and highlighting a significant unmet need. Upcoming ASCO 2025 data and FDA alignment on Accelerated Approval using ORR as an endpoint create a compelling near-term catalyst for investors.

Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Enrollment ongoing in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Strong financial position with approximately $462 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the first quarter ended March 31, 2025 and provided a business update. "We continued to execute across our clinical programs in the first quarter, maintaining strong momentum as we advance FORTIFI-HN01, the pivotal Phase 2/3 trial of ficerafusp alfa in HPV-negative recurrent/metastatic head and neck squamous cell carcinoma," said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics.

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple presentations related to ficerafusp alfa at the American Association for Cancer Research (AACR) Annual Meeting 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types.

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

See News Rankings

Charts implemented using Lightweight Charts™